Menu Search
Equities

Cellectis SA

ZVA:FRA

Cellectis SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)2.74
  • Today's Change0.01 / 0.37%
  • Shares traded10.00
  • 1 Year change+66.97%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024 07:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cellectis SA had revenues fall -64.26% from 25.73m to 9.19m, though the company grew net income from a loss of 106.14m to a smaller loss of 101.06m.
Gross margin--
Net profit margin-1,270.92%
Operating margin-1,058.44%
Return on assets-39.24%
Return on equity-108.01%
Return on investment-60.81%
More ▼

Cash flow in USDView more

In 2023, Cellectis SA increased its cash reserves by 46.66%, or 43.49m. Cash Flow from Financing totalled 82.87m or 901.39% of revenues. In addition the company used 24.75m for operations while cash used for investing totalled 15.51m.
Cash flow per share-0.4507
Price/Cash flow per share--
Book value per share1.09
Tangible book value per share1.09
More ▼

Balance sheet in USDView more

Cellectis SA has a Debt to Total Capital ratio of 54.29%, a lower figure than the previous year's 59.24%.
Current ratio1.50
Quick ratio--
Total debt/total equity1.19
Total debt/total capital0.5429
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.